Insider Selling: 4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $16,627.95 in Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 1,635 shares of the firm’s stock in a transaction dated Thursday, October 16th. The shares were sold at an average price of $10.17, for a total value of $16,627.95. Following the completion of the sale, the insider directly owned 5,188 shares in the company, valued at approximately $52,761.96. The trade was a 23.96% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Scott Bizily also recently made the following trade(s):

• On Thursday, October 9th, Scott Bizily sold 2,408 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $10.00, for a total value of $24,080.00.
• On Tuesday, September 23rd, Scott Bizily sold 2,407 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $8.00, for a total value of $19,256.00.

4D Molecular Therapeutics Trading Down 6.4%

Shares of 4D Molecular Therapeutics stock opened at $10.52 on Thursday. The firm has a market capitalization of $491.31 million, a PE ratio of -2.98 and a beta of 2.93. The business’s 50-day moving average price is $7.86 and its 200-day moving average price is $5.30. 4D Molecular Therapeutics, Inc. has a 12 month low of $2.23 and a 12 month high of $11.65.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.10). The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.52 million. 4D Molecular Therapeutics had a negative net margin of 594,375.81% and a negative return on equity of 40.15%. As a group, analysts predict that 4D Molecular Therapeutics, Inc. will post -2.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently commented on FDMT shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, October 8th. Chardan Capital restated a “buy” rating and set a $25.00 price target on shares of 4D Molecular Therapeutics in a research report on Tuesday, August 12th. Roth Capital reduced their price target on 4D Molecular Therapeutics from $44.00 to $38.00 and set a “buy” rating on the stock in a research report on Tuesday, August 12th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $26.00 price objective on shares of 4D Molecular Therapeutics in a research report on Tuesday. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, 4D Molecular Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $29.50.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Farther Finance Advisors LLC lifted its stake in shares of 4D Molecular Therapeutics by 117.4% in the 3rd quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock valued at $43,000 after purchasing an additional 2,674 shares during the period. Quadrature Capital Ltd purchased a new position in shares of 4D Molecular Therapeutics in the 2nd quarter valued at approximately $42,000. Los Angeles Capital Management LLC purchased a new position in shares of 4D Molecular Therapeutics in the 2nd quarter valued at approximately $42,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of 4D Molecular Therapeutics in the 1st quarter valued at approximately $39,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in shares of 4D Molecular Therapeutics in the 1st quarter valued at approximately $41,000. Hedge funds and other institutional investors own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.